Consistent with this hypothesis, the combination of proteasome and CRM1 inhibition induced synergistic cell death for both D418 and 17-3X cells (Figure 5E,F), suggesting that this combination may represent a rational strategy to treat osteosarcoma. The gene discussed is XPO1; the disease is osteosarcoma.